"Lomustine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An alkylating agent of value against both hematologic malignancies and solid tumors.
| Descriptor ID |
D008130
|
| MeSH Number(s) |
D02.654.692.440 D02.948.594.440
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Lomustine".
Below are MeSH descriptors whose meaning is more specific than "Lomustine".
This graph shows the total number of publications written about "Lomustine" by people in this website by year, and whether "Lomustine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lomustine" by people in Profiles.
-
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013 Sep 10; 31(26):3212-8.
-
Integrated phase II/III clinical trials in oncology: a case study. Clin Trials. 2012 Dec; 9(6):741-7.
-
A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood. Neuro Oncol. 2008 Aug; 10(4):569-76.
-
LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre. Bone Marrow Transplant. 2007 Jan; 39(1):41-7.
-
Anaplastic oligodendroglial tumors: a tale of two trials. J Clin Oncol. 2006 Jun 20; 24(18):2689-90.
-
Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys. 2002 May 01; 53(1):58-66.
-
Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res. 2000 Oct; 6(10):3878-84.
-
A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 1999 Aug 01; 45(1):127-35.
-
TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. J Clin Oncol. 1997 Mar; 15(3):1063-70.
-
Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 1995 Sep 30; 33(2):357-64.